** Shares of drug distributor Cencora COR.N rise 5.7% to $307.50
** Co raises annual adj.profit forecast on strong demand for costly specialty medicines and weight-loss drugs
** Expects 2025 adj.profit to be between $15.70 and $15.95 per share, up from its previous expectation of $15.30 to $15.60 per share
** Q2 revenue at its U.S. healthcare business came in at $68.3 billion, up 11.4% from a year earlier
** Reports Q2 adj.profit of $4.42 per share, beating analysts' estimates of $4.11 per share, as per data compiled by LSEG
** "The fact that COR has now increased guidance 4x so far in FY25 (this is only the second fiscal quarter report) shows underlying confidence in the business as well"- brokerage Leerink Partners
** Including session moves, stock up 36.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.